Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BayStreetWildon Feb 07, 2023 11:43pm
124 Views
Post# 35273559

RE:RE:more dodgy transparency moves

RE:RE:more dodgy transparency moves

Yeah, revised to more dilution. Most likely

mercedesman wrote:

hmmmmmmmm wrote: Management has pulled the latest September presentation down off the Investor Page of the company's site.

Toatally normal behavior...
Good!


 an update must be coming soon! 

maybe the $1.5 B revenue opportunity will be revised upward for one or more of the following reasons:

-Higher rate of Severe Sepsis in 2023 vs 2017
- higher per cartridge price due to expanded label
- higher per cartridge price due to exceeding expectations
-worldwide EAA sales once/if FDA approved PMX
- stage two monetization of iDialco for the benefit of Spectral shareholders
- inclusion of Cdn market ( the only place , really, where shares trade) 
- possible use of PMX to treat Covid patients suffering from gut dysbiosis, wherein endotoxins escape into the bloodstream and trigger a cytokine storm and then sepsis and then death. 
- mounting kidney disease due to aging obese popultation, Covid organ damage, long Covid, increasing antibiotic resistance, declining and overworked ICU staff ( higher hospital acquired infections) etc  

-etc.

MM 

 


 

<< Previous
Bullboard Posts
Next >>